Fate Therapeutics, Inc. (FATE) by event type
FATE moves most on analyst upgrades — a median of -2.50% at 30 minutes across 15 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the FATE overview →
How FATE reacts across 3 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 2,703 of 2,717 | 15 | -2.50% | 13% | -3.90% |
| Rating reiterations 3,238 of 3,522 | 59 | -0.39% | 41% | -2.14% |
| Price-target cuts 1,510 of 1,527 | 12 | -1.10% | 42% | -2.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 3 further classes were observed with fewer than 10 measured events and are not published.
That’s how FATE usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Rating reiterations → · Price-target cuts → · FATE overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Accuray Incorporated (ARAY) | 288 | 0.00% | 51% |
| Chemed Corp (CHE) | 288 | +0.02% | 53% |
| RenovaCare, Inc. (RCAR) | 286 | 0.00% | 41% |
| Cellectis S.A. - American Depositary Shares (CLLS) | 285 | -0.01% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.